Lv0
0 积分 2024-11-03 加入
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
2小时前
已完结
723P A phase II study of cadonilimab plus chemotherapy in persistent recurrent/ metastatic cervical cancer patients who failed previous immuno/chemotherapy
22天前
已关闭
The efficacy and safety of cadonilimab after first anti-PD-1 failure in the treatment of recurrent endometrial and cervical carcinoma: A retrospective, real-world study
23天前
已完结
Mechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies
23天前
已完结
How I Treat Non–Small Cell Lung Cancer Refractory to Immunotherapy
23天前
已完结
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
24天前
已完结
Treatment patterns and prognosis of patients with clear cell adenocarcinoma of the cervix: A population-based cohort study
29天前
已完结
皖公网安备34019202002308
